Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris N Barnes

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
American Journal of Respiratory and Critical Care Medicine|March 28, 2025
Dual αvβ6 and αvβ1 Inhibition Over 12 Weeks Reduces Active Type 1 Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical TrialSydney B Montesi, Gregory P Cosgrove, Scott M Turner, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
Annals of the American Thoracic Society|November 5, 2024
Bexotegrast Shows Dose-Dependent Integrin α<sub>v</sub>β<sub>6</sub> Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical TrialJoshua J Mooney, Susan Jacobs, Éric A Lefebvre, et al.
American Journal of Respiratory and Critical Care Medicine|June 6, 2024
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical TrialLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
Therapeutic Advances in Respiratory Disease|November 8, 2024
Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF studyLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
Journal of Hepatology|September 28, 2025
Phase II INTEGRIS-PSC trial of bexotegrast, an α<sub>v</sub>β<sub>6</sub>/α<sub>v</sub>β<sub>1</sub> integrin inhibitor, in primary sclerosing cholangitisGideon M Hirschfield, Kris V Kowdley, Palak J Trivedi, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
American Journal of Respiratory and Critical Care Medicine|March 28, 2025
Dual αvβ6 and αvβ1 Inhibition Over 12 Weeks Reduces Active Type 1 Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical TrialSydney B Montesi, Gregory P Cosgrove, Scott M Turner, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
Annals of the American Thoracic Society|November 5, 2024
Bexotegrast Shows Dose-Dependent Integrin α<sub>v</sub>β<sub>6</sub> Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical TrialJoshua J Mooney, Susan Jacobs, Éric A Lefebvre, et al.
American Journal of Respiratory and Critical Care Medicine|June 6, 2024
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical TrialLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
Therapeutic Advances in Respiratory Disease|November 8, 2024
Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF studyLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
Journal of Hepatology|September 28, 2025
Phase II INTEGRIS-PSC trial of bexotegrast, an α<sub>v</sub>β<sub>6</sub>/α<sub>v</sub>β<sub>1</sub> integrin inhibitor, in primary sclerosing cholangitisGideon M Hirschfield, Kris V Kowdley, Palak J Trivedi, et al.
Pageof 3